| Literature DB >> 31717948 |
Lina M C Lobo1, Raquel M Schincaglia1,2, Maria do Rosário G Peixoto2, Maria Claret C M Hadler1,2.
Abstract
Multiple micronutrient powder supplementation is a health promotion strategy, but data on its effectiveness regarding vitamin E are rare. The objective was to evaluate the impact of home fortification with powdered micronutrients on α-tocopherol concentrations, growth, and inflammation in Brazilian children aged 6-15 months. This is a pragmatic, controlled clinical trial, in which the intervention group received micronutrient powder sachets for up to 3 months. Vitamin E deficiency was considered when α-tocopherol was less than 11.6 µmol/L. The Poisson regression model was used to estimate adjusted values for prevalence ratios (PR) for the outcome variable. A total of 224 children participated in the study. The intervention group had a higher median α-tocopherol level (17.2 versus 3.6 µmol/L; p < 0.001) and an 82.0% reduction in the prevalence of vitamin deficiency (PR = 0.18; 95% CI 0.11-0.30) when compared with the control group. Consumption of multiple micronutrients in powder increases serum α-tocopherol concentrations, promotes better linear growth, and reduces morbidity in children.Entities:
Keywords: child; deficiency diseases; health promotion; micronutrients; tocopherols; vitamin E
Mesh:
Substances:
Year: 2019 PMID: 31717948 PMCID: PMC6893530 DOI: 10.3390/nu11112730
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Outline of the matrix project study.
Characteristics of children participating in the ENFAC study (Goiânia, 2013; n = 224).
| Variable | CG ( | IG ( | |
|---|---|---|---|
| Age of child (months), mean, and SD | 13.65 ± 0.87 | 12.94 ± 0.94 | <0.001 1 |
| Female gender, | 55 (47.01) | 53 (49.53) | 0.71 2 |
| Birth weight, mean and SD | 3247.5 ± 469.8 | 3288.5 ± 426.1 | 0.49 3 |
| Maternal education <9 years, | 33 (28.45) | 21 (19.81) | 0.13 2 |
| Mother’s age (years), median (IQR) | 28 (24; 32) | 27 (22; 31) | 0.18 1 |
| Current breastfeeding, | 67 (57.26) | 59 (55.14) | 0.75 2 |
| Number of prenatal consultations, median (IQR) | 8 (6;10) | 8 (6;9) | 0.80 1 |
| Race, | 0.95 4 | ||
| White | 9 (7.76) | 10 (9.35) | |
| Brown | 102 (87.93) | 93 (86.92) | |
| Black | 5 (4.31) | 4 (3.74) |
1 Mann–Whitney; 2 Pearson’s chi-square test; 3 Student’s t-test; 4 Fisher’s exact test. CG: control group; ENFAC: Estudo Nacional de Fortificação Caseira da Alimentação Complementar; IG: intervention group; IQR: interquartile range; SD: standard deviation.
Anthropometric, clinical, and biochemical data on participating children at the end of the ENFAC study (Goiânia, 2013; n = 224).
| Variable | CG ( | IG ( | |
|---|---|---|---|
|
| |||
| Weight (kg), mean and SD | 10.02 ± 1.20 | 9.85 ± 1.19 | 0.29 1 |
| Length (cm), median (IQR) | 77 (75; 79) | 77.8 (75; 79.5) | 0.68 2 |
| LAZ ( | 0.07 ± 1.13 | 0.41 ± 1.09 | 0.02 1 |
|
| |||
| Presence of fever, | 39 (33.33) | 24 (22.43) | 0.07 3 |
| Presence of cough, | 53 (45.30) | 21 (19.63) | <0.001 3 |
| Presence of wheezing, | 35 (29.91) | 16 (14.95) | 0.008 3 |
| Presence of diarrhea, | 27 (23.08) | 22 (20.56) | 0.65 3 |
|
| |||
| Serum α-tocopherol (µmol/L), median (IQR) | 3.6 (0.09; 9.7) | 17.2 (12.9; 21.2) | <0.001 2 |
| CRP (mg/L), median (IQR) | 0.5 (0.2; 1.5) | 0.3 (0.2; 1.0) | 0.19 2 |
| AGP (mg/dL), median (IQR) | 74.5 (61.8; 109.5) | 72.4 (61.4; 92.3) | 0.08 2 |
1 Student’s t-test; 2 Mann–Whitney test; 3 Pearson’s chi-square. AGP: alpha-1-glycoprotein; CG: control group; CRP: C-reactive protein; ENFAC: Estudo Nacional de Fortificação Caseira da Alimentação Complementar; IG: intervention group; IQR: interquartile range; LAZ: length-for-age Z-score; SD: standard deviation.
Prevalence and prevalence ratio for vitamin E deficiency and inflammatory status between control and intervention groups at the end of the ENFAC study (Goiânia, 2013; n = 224).
| Variable | CG ( | IG ( | |
|---|---|---|---|
|
| |||
| Vitamin E deficiency (<11.6 µmol/L), | 95 (85.6) | 16 (14.4) | <0.001 1 |
| Vitamin E deficiency, adjusted PR (95% CI) | 1 | 0.18 (0.11; 0.30) | <0.001 2 |
| CRP > 5 mg/L, | 14 (12.39) | 6 (5.83) | 0.096 1 |
| CRP > 5 mg/L, adjusted PR (95% CI) | 1 | 0.40 (0.13; 1.29) | 0.13 2 |
| AGP > 100 mg/dL, | 37 (33.04) | 20 (19.42) | 0.024 1 |
| AGP, adjusted PR (95% CI) | 1 | 0.52 (0.31; 0.85) | 0.009 3 |
1 Pearson’s chi-square; 2 Null hypothesis test between groups using the mixed-effect Poisson regression model adjusted for the child’s age, gender, length-for-age Z-score, race, current breastfeeding, birth weight, mother’s age, and mother’s schooling. AGP: alpha-1-glycoprotein; CG, control group; CRP, C-reactive protein; IG, intervention group; PR: prevalence ratio.